Thus, emerging therapies aim to reprogram these cells through controlled delivery of immune cues consisting of self-antigens (i.e., myelin oligodendrocyte glycoprotein - MOG) and immunomodulators (i.e., oligonucleotides, small molecule drugs) to treat MS without broad immunosuppression. Here, MOG is linked to myeloid sarcoma.